Synthesis, in vitro antitubercular activity and 3D-QSAR study of 1,4-dihydropyridines

Molecular Diversity

Volumn 14, Issue 2, 2010, Pages 285-305

  Manvar, Atul T ^a   Pissurlenkar, Raghuvir R S ^b   Virsodia, Vijay R ^c   Upadhyay, Kuldip D ^d   Manvar, Dinesh R ^c   Mishra, Arun K ^c   Acharya, Hrishikesh D ^c   Parecha, Alpesh R ^e   Dholakia, Chintan D ^f   Shah, Anamik K ^a   Coutinho, Evans C ^b  

^a SAURASHTRA UNIVERSITY   (India)

^b BOMBAY COLLEGE OF PHARMACY   (India)

^c Jubilant Organosys   (India)

^d Torrent Research Centre   (India)

^e Sun Pharmaceuticals   (India)

^f Unimark Remedies Ltd   (India)

Author keywords

1,4 DHPs; 3D QSAR; Antitubercular activity; CoMFA; CoMSIA

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT; DIHYDROPYRIDINE DERIVATIVE;

ARTICLE; ATOM; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER MODEL; CONFORMATION; CONTROLLED STUDY; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECT; SYNTHESIS;

ANTITUBERCULAR AGENTS; COMPUTER SIMULATION; DIHYDROPYRIDINES; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954664594     PISSN: 13811991     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11030-009-9162-8     Document Type: Article

References (36)

1. Daffe M, Draper P (1998) The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 39:131-203. doi:10.1016/S0065-2911(08)60016-8
2. Dolin PJ, Raviglione MC, Kochi A (1994) Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 72:213-220 (Pubitemid 24156209)
3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282:677-686. doi:10.1001/jama.282.7.677 (Pubitemid 29384157)
4. Guerrin-Tran E, Thiolet JM, Rousseau C, Henry S, Poirier C, Che D, Vinas JM, Jarlier V, Robert J (2006) An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001-2002. Eur J Epidemiol 21:783-785. doi:10.1007/s10654-006-9069-y (Pubitemid 44885199)
5. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C (2003) Tuberculosis. Lancet 362:887-899. doi:10.1016/S0140-6736(03)14333-14334
6. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA (2003) American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit CareMed 167:603-662. doi:10.1164/rccm. 167.4.603
7. Honer zu Bentrup K, Russell DG (2001) Mycobacterial persistence: adaptation to a changing environment. Trends Microbiol 9:597-605. doi:10.1016/S0966-842X(01)02238-7 (Pubitemid 33135416)
8. Saquib M, Gupta MK, Sagar R, Prabhakar YS, Shaw AK, Kumar R, Maulik PR, Gaikwad AN, Sinha S, Srivastava AK, Chaturvedi V, Srivastava R, Srivastava BS (2007) C-3 alkyl/arylalkyl-2,3-dideoxy hex-2-enopyranosides as antitubercular agents: synthesis, biological evaluation, and QSAR study. J Med Chem 50:2942-2950. doi:10.1021/jm070110h (Pubitemid 47001238)
9. Kaufmann SH, van Embden JD (1993) Tuberculosis: a neglected disease strikes back. Trends Microbiol 1:2-5. doi:10.1016/0966-842X(93)90015-J (Pubitemid 23187151)
10. Bloom BR, Murray CJ (1992) Tuberculosis: commentary on a reemergent killer. Science 257:1055-1064. doi:10.1126/science.257.5073.1055
11. Fischl MA, Daikos GL, Uttamchandani RB, Poblete RB, Moreno JN, Reyes RR, Boota AM, Thompson LM, Cleary TJ, Oldham SA et al (1992) Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 117:184-190
12. Maddry JA, Suling WJ, Reynolds RC (1996) Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium. Res Microbiol 147:106-112. doi:10.1016/0923-2508(96)80211-80217
13. Reynolds RC, Bansal N, Rose J, Friedrich J, Suling WJ, Maddry JA (1999) Ethambutol-sugar hybrids as potential inhibitors of mycobacterial cell-wall biosynthesis. Carbohydr Res 317:164-179. doi:10.1016/S0008-6215(99)00069-5 (Pubitemid 29329409)
14. Jones PB, Parrish NM, Houston TA, Stapon A, Bansal NP, Dick JD, Townsend CA (2000) A new class of antituberculosis agents. J Med Chem 43:3304-3314. doi:10.1021/jm000149l
15. Pasqualoto KF, Ferreira EI (2001) An approach for the rational design of new antituberculosis agents. Curr Drug Targets 2:427-437. doi:10.2174/ 1389450013348227 (Pubitemid 33107534)
16. Teodori E, Dei S, Scapecchi S, Gualtieri F (2002) The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 57:385-415. doi:10.1016/S0014-827X(02)01229-6 (Pubitemid 34451020)
17. Smith CV, Sharma V, Sacchettini JC (2004) TB drug discovery: addressing issues of persistence and resistance. Tuberculosis (Edinb) 84:45-55. doi:10.1016/j.tube.2003.08.019 (Pubitemid 38082932)
18. Dodia N, Shah A (1999) Single step synthesis and antimicrobial and antitubercular screening of substituted 2,4-dihydroxyquinolines. Indian J Heterocycl Chem 9:139-142
19. Dodia N, Shah A (2000) Synthesis and antitubercular study of some substituted 3-nitro and 3-bromo-4-hydroxy-2-quinolines. Indian J Heterocycl Chem 10:69-70
20. Virsodia V, Pissurlenkar RR, Manvar D, Dholakia C, Adlakha P, Shah A, Coutinho EC (2008) Synthesis, screening for antitubercular activity and 3D-QSAR studies of substituted N-phenyl-6- methyl-2-oxo-4-phenyl-1, 2, 3, 4-tetrahydro-pyrimidine-5-carboxamides. Eur J Med Chem 43:2103-2115. doi:10.1016/j.ejmech.2007.08.004
21. Gaveriya H, Desai B, Vora V, Shah A (2002) Synthesis and antitubercular activity studies of some unsymmetrical 1,4-dihydropyridines. Indian J Pharm Sci 64:59-62
22. Kharkar PS, Desai B, Gaveria H, Varu B, Loriya R, Naliapara Y, Shah A, Kulkarni VM (2002) Three-dimensional quantitative structure-activity relationship of 1,4-dihydropyridines as antitubercular agents. JMed Chem 45:4858-4867. doi:10.1021/jm020217z (Pubitemid 35192775)
23. Mahendra M, Doreswamy BH, Shridhar MA, Prasad JS, Parecha AR, Patel JA,Manvar D, Dholaria K, Shah A (2006) Synthesis and structural conformation of N-substituted 1,4-dihyropyridine derivatives. Cryst Res Technol 41:92-97. doi:10.1002/crat.200310539 (Pubitemid 43106198)
24. Sybyl 7.1, Tripos Inc., St. Louis, Missouri, USA
25. Martin EJ, Blaney JM, SianiMA, Spellmeyer DC,Wong AK, Moos WH (1995) Measuring diversity: experimental design of combinatorial libraries for drug discovery. J Med Chem 38:1431-1436. doi:10.1021/jm00009a003
26. CoMFA and QSAR Manual Sybyl 7.1, Associates Inc., USA
27. Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967. doi:10.1021/ja00226a005
28. Cramer RD 3rd, Patterson DE, Bunce JD (1989) Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res 291:161-165
29. KlebeG(1998) Comparativemolecular similarity indices analysis: CoMSIA. Perspect Drug Discov Des 12:87-104. doi:10.1023/A:1017025803403
30. KlebeG,Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130-4146. doi:10.1021/jm00050a010 (Pubitemid 24379702)
31. Bohm M, Strzebecher J, Klebe G (1999) Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparativemolecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 42:458-477. doi:10.1021/jm981062r (Pubitemid 29085107)
32. Wold S, Johansson E, CocchiM (1993) 3D-QSAR in drug design: theory methods and applications. ESCOM Lieden, The Netherlands
33. Bush BL, Nachbar RB Jr (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 7:587-619. doi:10.1007/BF00124364
34. Legar C, Romano JP, Politis DN (1992) Bootstrap technology and applications. Technometrics 34:378-398. doi:10.2307/1268938
35. Didziapetris R, Reynolds DP, Japertas P, Zmuidinavicius D, Petrauskas A (2006) In silico technology for identification of potentially toxic compounds in drug discovery. Curr Comput AidedDrug Des 2:95-103. doi:10.2174/ 157340906777441708 (Pubitemid 44082926)
36. Zmuidinavicius D, Japertas P, Petrauskas A, Didziapetris R (2003) Progress in toxinformatics: the challenge of predicting acute toxicity. Curr Top Med Chem 3:1301-1314. doi:10.2174/1568026033451989